Johnson & Johnson Stock Price, News & Analysis

Johnson & Johnson (NYSE: JNJ) has extended the expiration of its offer to acquire Abiomed, Inc. (NASDAQ: ABMD) for $380.00 per share, plus a potential $35.00 contingent value right. The new expiration date is set for December 21, 2022. As of December 13, 2022, about 19.3 million shares, or 42.75% of Abiomed's outstanding shares, have been tendered. The acquisition is conditional on the successful tendering of a majority of shares and receiving necessary regulatory approvals. Investors are encouraged to review related filings on the SEC's website for more details.

Johnson & Johnson (NYSE: JNJ) will host an investor conference call at 8:30 a.m. (Eastern Time) on January 24 to discuss its fourth-quarter results. Key executives, including CEO Joaquin Duato and CFO Joseph J. Wolk, will lead the call. Interested parties can join via the company’s website or by phone. A replay will be available until February 7. The results are anticipated to provide insights into the company’s performance, which is crucial for stakeholders and market analysts.

Johnson & Johnson (NYSE: JNJ) will attend the 41st Annual J.P. Morgan Healthcare Conference on January 9 at 12:45 p.m. ET in San Francisco, CA. CEO Joaquin Duato will represent the company during the session. The event will feature a live audio webcast accessible via the Johnson & Johnson investor website. An audio replay will be available approximately 48 hours after the event.

Johnson & Johnson (NYSE: JNJ) announced that CEO Joaquin Duato will take on the additional role of Chairman, effective January 2023, succeeding Alex Gorsky who steps down after 30 years. Duato, with over three decades at J&J, is recognized for his leadership and commitment to stakeholder value. The transition highlights the company's succession planning, with Duato poised to guide J&J through pivotal times. Both Gorsky's contributions and Duato's vision indicate a strategic focus on healthcare innovation and inclusivity.

ABIOMED, Inc. (NASDAQ: ABMD) reported financial results for the quarter ending September 30, 2022, with revenues reaching $266 million, marking an 11% increase in constant currency. This growth reflects the seventh consecutive quarter of double-digit constant currency growth. U.S. product revenue also increased by 10% to $208 million. However, procedural volumes were affected in July due to physician vacations and labor shortages, which improved by August and September. The company celebrated significant innovation milestones and FDA approvals.

Johnson & Johnson (NYSE: JNJ) has announced the acquisition of Abiomed (NASDAQ: ABMD) for $380.00 per share, valuing the deal at approximately $16.6 billion. The acquisition aims to enhance Johnson & Johnson’s MedTech segment, particularly in the cardiovascular space, addressing significant health needs related to heart failure. The acquisition is expected to be accretive to adjusted earnings starting in 2024. Abiomed's innovative technologies and strong growth potential will complement Johnson & Johnson's existing portfolio, facilitating market expansion in high-growth cardiovascular sectors.

Johnson & Johnson (NYSE: JNJ) reported Q3 2022 sales of $23.8 billion, a 1.9% increase from Q3 2021. Earnings per share (EPS) rose 22.6% to $1.68, while adjusted EPS decreased 1.9% to $2.55. Operational sales grew 8.1%, driven by strong performances in the pharmaceutical sector, particularly from drugs like DARZALEX and TREMFYA. The company is maintaining its full-year guidance for adjusted operational sales and EPS, despite adverse currency impacts. The quarter also saw significant regulatory approvals and a new $5 billion share repurchase program.

Johnson & Johnson (NYSE: JNJ) will participate in the Credit Suisse 31st Annual Global Healthcare Conference on November 10, 2022. Executive Vice President Jennifer Taubert will represent the company during a session at 12:50 p.m. (Eastern Time) at the Terranea Resort in Rancho Palos Verdes, CA. Investors can access the event via an audio webcast on the Johnson & Johnson website, with a replay available approximately 48 hours post-event.

Johnson & Johnson (NYSE: JNJ) announced its new consumer health company name, Kenvue, marking a significant step in its planned separation. Kenvue, signifying 'knowledge' and 'view,' aims to provide innovative health solutions globally. With a revenue of $14.6 billion in 2021, Kenvue will operate across 100+ countries. CEO Thibaut Mongon emphasized Kenvue's commitment to everyday care, leveraging its rich portfolio of iconic brands like Tylenol and Neutrogena. The separation is expected to complete in 2023.